Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H28N2O3.ClH |
| Molecular Weight | 368.898 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C(C)C2=C(CC[C@](C)(O2)C(=O)N[C@@H]3CCCNC3)C(C)=C1O
InChI
InChIKey=HVFWCHDZDIRYBZ-MQZJHDQISA-N
InChI=1S/C19H28N2O3.ClH/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14;/h14,20,22H,5-10H2,1-4H3,(H,21,23);1H/t14-,19+;/m1./s1
| Molecular Formula | C19H28N2O3 |
| Molecular Weight | 332.4372 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
KH-176 is a drug candidate developed by pharmaceutical company Khondrion to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. KH176 has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. KH176 acts as a potent intracellular redox-modulating agent essential for the control of oxidative and redox pathologies.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:17:04 GMT 2025
by
admin
on
Mon Mar 31 22:17:04 GMT 2025
|
| Record UNII |
858M8246UL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/15/1543
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
||
|
FDA ORPHAN DRUG |
450714
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EU/3/14/1336(POSITIVE)
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
PRIMARY | On 15 October 2014, orphan designation (EU/3/14/1336) was granted by the European Commission to Khondrion BV, the Netherlands, for (S)-6-Hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3?yl)chroman-2-carboxamide hydrochloride for the treatment of Leigh syndrome. | ||
|
EU/3/15/1543(POSITIVE)
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
PRIMARY | On 10 August 2015, orphan designation (EU/3/15/1543) was granted by the European Commission to Khondrion BV, the Netherlands, for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. | ||
|
858M8246UL
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
PRIMARY | |||
|
100000180594
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
PRIMARY | |||
|
72710874
Created by
admin on Mon Mar 31 22:17:04 GMT 2025 , Edited by admin on Mon Mar 31 22:17:04 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |